173P Clinical Outcomes in Stratification Subgroups in the ARASENS Study in Metastatic Hormone-Sensitive Prostate Cancer (Mhspc)

F. Parnis,B. Tombal,M. Hussain,F. Saad,K. Fizazi,C. N. Sternberg,E. D. Crawford,E. Kopyltsov,A. Rezazadeh Kalebasty,B. Y. Alekseev,A. Montesa Pino,D. Ye,F. J. S. Melo Cruz,T. Tammela, H. Suzuki,H. Joensuu, S. Thiele,R. Li,I. Kuss,M. Smith

Annals of oncology（2022）

引用 0|浏览12

暂无评分

摘要

In ARASENS (NCT02799602), darolutamide (DARO) + androgen-deprivation therapy (ADT) + docetaxel significantly reduced risk of death by 32.5% (HR 0.68, 95% CI 0.57–0.80; P<0.001) vs placebo (PBO) + ADT + docetaxel in patients (pts) with mHSPC. We investigated clinical outcomes in prespecified stratification subgroups based on extent of disease and alkaline phosphatase (ALP), both known prognostic factors.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要